Page last updated: 2024-11-12
edgeworin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
edgeworin: from Dirca occidentalis Gray; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Related Flora
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Dirca | genus | [no description available] | Thymelaeaceae | A plant family of the order Myrtales, subclass Rosidae, class Magnoliopsida. They are mainly trees and shrubs. Many members contain mucilage and COUMARINS.[MeSH] |
| Dirca occidentalis | species | [no description available] | Thymelaeaceae | A plant family of the order Myrtales, subclass Rosidae, class Magnoliopsida. They are mainly trees and shrubs. Many members contain mucilage and COUMARINS.[MeSH] |
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 10925304 |
| CHEMBL ID | 259025 |
| SCHEMBL ID | 13784418 |
| MeSH ID | M0246931 |
Synonyms (14)
| Synonym |
|---|
| edgeworin |
| CHEMBL259025 , |
| 7-hydroxy-3-(2-oxo-2h-chromen-7-yloxy)chromen-2-one |
| bdbm50237597 |
| 7-hydroxy-3,7''-dicoumaryl ether |
| SCHEMBL13784418 |
| 120028-43-5 |
| AKOS032962620 |
| 3-(7-coumarinyloxy)-7-hydroxycoumarin |
| 7-hydroxy-3-(2-oxochromen-7-yl)oxychromen-2-one |
| 7-hydroxy-3-((2-oxo-2h-chromen-7-yl)oxy)-2h-chromen-2-one |
| STARBLD0001917 |
| CS-0369085 |
| HY-N10169 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (2)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| DNA polymerase beta | Homo sapiens (human) | IC50 (µMol) | 35.1550 | 1.4000 | 6.5667 | 9.0000 | AID328030; AID328031 |
| DNA polymerase beta | Rattus norvegicus (Norway rat) | IC50 (µMol) | 22.5000 | 3.7000 | 6.2000 | 8.5000 | AID333321 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (22)
Molecular Functions (10)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| damaged DNA binding | DNA polymerase beta | Homo sapiens (human) |
| DNA-directed DNA polymerase activity | DNA polymerase beta | Homo sapiens (human) |
| DNA-(apurinic or apyrimidinic site) endonuclease activity | DNA polymerase beta | Homo sapiens (human) |
| protein binding | DNA polymerase beta | Homo sapiens (human) |
| microtubule binding | DNA polymerase beta | Homo sapiens (human) |
| lyase activity | DNA polymerase beta | Homo sapiens (human) |
| enzyme binding | DNA polymerase beta | Homo sapiens (human) |
| metal ion binding | DNA polymerase beta | Homo sapiens (human) |
| 5'-deoxyribose-5-phosphate lyase activity | DNA polymerase beta | Homo sapiens (human) |
| class I DNA-(apurinic or apyrimidinic site) endonuclease activity | DNA polymerase beta | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Ceullar Components (6)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| nucleus | DNA polymerase beta | Homo sapiens (human) |
| nucleoplasm | DNA polymerase beta | Homo sapiens (human) |
| cytoplasm | DNA polymerase beta | Homo sapiens (human) |
| microtubule | DNA polymerase beta | Homo sapiens (human) |
| spindle microtubule | DNA polymerase beta | Homo sapiens (human) |
| protein-containing complex | DNA polymerase beta | Homo sapiens (human) |
| nucleus | DNA polymerase beta | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Bioassays (14)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID328032 | Inhibition of DNA-polymerase beta binary complex formation by DNA binding mobility shift assay | 2008 | Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8 | Inhibitors of DNA polymerase beta: activity and mechanism. |
| AID333322 | Cytotoxicity against human A549 cells at 6 uM after 48 hrs | 2004 | Journal of natural products, Sep, Volume: 67, Issue:9 | Biscoumarin derivatives from Edgeworthia gardneri that inhibit the lyase activity of DNA polymerase beta. |
| AID333324 | Cytotoxicity against human A549 cells at 6 uM after 48 hrs in presence of 0.5 uM blenoxane | 2004 | Journal of natural products, Sep, Volume: 67, Issue:9 | Biscoumarin derivatives from Edgeworthia gardneri that inhibit the lyase activity of DNA polymerase beta. |
| AID328030 | Inhibition of lyase activity of DNA polymerase beta | 2008 | Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8 | Inhibitors of DNA polymerase beta: activity and mechanism. |
| AID1675381 | Disruption of interaction between Nrf2/Keap1 (unknown origin) in mesangial cells assessed as reduction in high glucose-induced collagen IV secretion at 10 uM by ELISA | 2020 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 30, Issue:20 | Discovery of a coumarin derivative as Nrf2 activator mitigating oxidative stress and fibrosis in mesangial cells under high glucose. |
| AID333321 | Inhibition of lyase activity of rat DNA polymerase beta after 30 mins | 2004 | Journal of natural products, Sep, Volume: 67, Issue:9 | Biscoumarin derivatives from Edgeworthia gardneri that inhibit the lyase activity of DNA polymerase beta. |
| AID328031 | Inhibition of polymerase activity of DNA polymerase beta | 2008 | Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8 | Inhibitors of DNA polymerase beta: activity and mechanism. |
| AID333413 | Inhibition of rat DNA polymerase beta-mediated DNA polymerization up to 100 ug/mL after 1 hr | 2004 | Journal of natural products, Sep, Volume: 67, Issue:9 | Biscoumarin derivatives from Edgeworthia gardneri that inhibit the lyase activity of DNA polymerase beta. |
| AID328033 | Cytotoxicity against human A549 cells after 1 hr by MTT assay | 2008 | Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8 | Inhibitors of DNA polymerase beta: activity and mechanism. |
| AID328038 | Inhibition of bleomycin-induced unscheduled DNA synthesis in human A549 cells at 6 uM | 2008 | Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8 | Inhibitors of DNA polymerase beta: activity and mechanism. |
| AID328035 | Effect on DNA polymerase beta expression in human A549 cells at 6 uM after 48 hrs by Western blot analysis | 2008 | Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8 | Inhibitors of DNA polymerase beta: activity and mechanism. |
| AID1675386 | Disruption of interaction between Nrf2/Keap1 (unknown origin) in mesangial cells assessed as reduction in high glucose-induced intracellular MDA level at 10 uM | 2020 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 30, Issue:20 | Discovery of a coumarin derivative as Nrf2 activator mitigating oxidative stress and fibrosis in mesangial cells under high glucose. |
| AID1675391 | Inhibition of glucose-induced cell proliferation in Mesangial cell (unknown origin) at 10 uM by CCK8 assay | 2020 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 30, Issue:20 | Discovery of a coumarin derivative as Nrf2 activator mitigating oxidative stress and fibrosis in mesangial cells under high glucose. |
| AID1675394 | Cytotoxicity against Mesangial cell (unknown origin) at 0.01 to 100 uM by CCK8 assay | 2020 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 30, Issue:20 | Discovery of a coumarin derivative as Nrf2 activator mitigating oxidative stress and fibrosis in mesangial cells under high glucose. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (4)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.53
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.53) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||